Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.37 |
| ▸ | AKT2 | P31751 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149214 | 0.95 | MCHR1 (0.41) | HRH3SMN1; SMN2GAAROCK1KCNH2 | |
| SCHEMBL5149127 | 0.90 | ROCK1 (0.43) | HRH3ROCK1KCNH2ROCK2CCR2 | |
| SCHEMBL5149179 | 0.89 | SMN1; SMN2 (0.42) | HRH3SMN1; SMN2GAAROCK1KCNH2 | |
| SCHEMBL5149115 | 0.87 | HRH3 (0.42) | HRH3AKT1AKT2 | |
| SCHEMBL5152286 | 0.83 | ACHE (0.47) | HRH3SMN1; SMN2GAADRD2DRD4 | |
| SCHEMBL5151087 | 0.80 | MALT1 (0.43) | SMN1; SMN2OPRK1DRD2DRD4ROCK2 | |
| SCHEMBL5149200 | 0.80 | SRC (0.43) | — | |
| SCHEMBL5150959 | 0.79 | FGFR1 (0.39) | SMN1; SMN2 | |
| SCHEMBL5148946 | 0.78 | SMN1; SMN2 (0.37) | HRH3SMN1; SMN2 | |
| SCHEMBL5148967 | 0.78 | HRH3 (0.36) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | HRH3 43/4885SMN1; SMN2 1645/4885GAA 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.